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Alterations of PPAR and its coactivator PGC-1 in cisplatin- The Peroxisome proliferator activated receptor-alpha
induced acute renal failure. (PPAR) is a fatty acid activated nuclear receptor that
Background. In this study we examined whether a recently plays a key role in the transcriptional regulation of genescharacterized coactivator of Peroxisome proliferator activated
involved in cellular lipid and energy metabolism. PPARreceptor  (PPAR), Peroxisome proliferator activated recep-
tor-gamma-coactivator-1 (PGC-1) plays a role in the regulation binds as heterodimer with the retinoid X receptor (RXR)
of fatty acid oxidation during cisplatin-induced nephrotoxicity. to a specific DNA sequence termed the peroxisome pro-
Methods. Studies in mouse kidneys used quantitative reverse liferator response element (PPRE) located upstream oftranscription-polymerase chain reaction (RT-PCR) to measure
target genes that are involved mainly in fatty acid oxida-peroxisomal acyl coenzyme A (acyl-CoA) and PGC-1 mRNA
levels and in situ hybridization to localize PGC-1 mRNA. Studies tion [1–5].
in LLCPK1 cells used quantitative RT-PCR and biochemical Previous studies in freshly isolated proximal tubules
assays to measure mRNA levels and enzyme activities of peroxi- have demonstrated the importance of fatty acid oxida-somal acyl-CoA, mitochondrial carnitine palmitoyl transferase
tion in cellular function. Under hypoxic conditions re-(CPT) and PGC-1. Eletrophoretic mobility shift assays (EMSA)
duced mitochondrial -oxidation in the proximal tubuleand Western blot analysis of nuclear extracts, and transient
transfection of PGC-1 were used to examine the effect of cis- predisposes to the accumulation of upstream extra-mito-
platin on PPAR-regulated fatty acid oxidation. chondrial long chain fatty acid intermediates such as long
Results. Cisplatin decreased mRNA levels of peroxisomal
chain acylcarnitines. Accumulation of long chain acyl-acyl-CoA enzyme in mouse kidney and also reduced the mRNA
carnitines inhibits proximal tubule sodium, potassiumlevels and enzyme activities of acyl-CoA and mitochondrial
CPT-1 in LLCPK1 cells. DNA-protein binding studies demon- (Na,K)-ATPase during hypoxia. Pharmacologic inhibi-
strated that exposure to cisplatin reduces PPAR/retinoid X tion of long chain acylcarnitines accumulation in proxi-
receptor (RXR) binding activity. Immunoblotting studies
mal tubular cells subjected to hypoxia improves cell sur-demonstrated that cisplatin had no effect on nuclear levels of
vival [6, 7]. Using the experimental model of bilateralPPAR or RXR protein. In situ hybridization studies in mouse
kidney demonstrated the localization of PGC-1 mRNA to proxi- renal ischemia, we have recently shown (1) that ischemia/
mal tubules and thick ascending limb of Henley (TALH) cells. reperfusion (I/R) injury caused severe reduction in mRNA,
Cisplatin diminished the expression of PGC-1 mRNA levels
protein levels, and enzyme activities of PPAR tar-in mouse kidney and also in LLCPK1 cells. Transient expres-
get genes acyl coenzyme A (acyl-CoA) oxidase andsion of PGC-1 shows the nuclear localization of PGC-1 protein
and increased PPAR transcriptional activity in LLCPK1 cells. CYP4A1; (2) that the administration of PPAR ligands
Conclusions. These results demonstrate that cisplatin deac- prior to I/R reversed the inhibitory effect of I/R injury
tivates PPAR by reducing its DNA binding activity and the
on mRNA, protein levels and enzyme activities of fattyavailability of its tissue specific coactivator PGC-1.
acid oxidation enzymes and ameliorated both renal func-
tion and histopathologic alterations of acute tubular ne-
crosis; and (3) that PPAR null mice subjected to a
similar degree of I/R injury exhibited enhanced necrosis
of the corticomedullary junction and further deteriora-Key words: PPAR, Peroxisome proliferator activated receptor-gamma-
coactivator-1, cisplatin, acute renal failure, proximal tubules. tion of renal function when compared to PPAR wild-
type mice [8]. Altogether, these preliminary observations
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phology and function during I/R-induced acute renal fered formalin for histopathologic evaluation and in situ
hybridization studies. One kidney was frozen in liquidfailure (ARF).
In the present studies we examined whether inhibition nitrogen for RNA isolation.
of fatty acid oxidation represents a common pathophysi-
RNA preparation and RT-PCR analysisologic response of the kidney and, in particular, the prox-
imal tubule during cisplatin-induced ARF. Our studies For these experiments total mRNA was isolated from
mouse kidney tissue and from LLCPK1 cells grown todemonstrate that similarly to I/R injury, cisplatin inhibits
fatty acid oxidation in mouse kidney and in proximal near confluency in two 10 cm2 Petri dishes as previously
described [8]. Relative levels of specific mRNAs weretubule cells in culture.
The mechanism(s) responsible for the observed inhibi- assessed by reverse transcription-polymerase chain re-
action (RT-PCR) using methods previously describedtion of fatty acid oxidation during tissue injury are not
known. A recent study suggests that the decreased fatty [15–17]. The quantitative RT-PCR assay was validated
for each mRNA message using various quantities of iso-acid oxidation response to hypoxia in cardiac myocytes
results from the deactivation of PPAR via reduced lated mRNA and by confirmation of the right size and
the expected amplified nucleotide sequence obtained byavailability of its obligate partner RXR [9]. Our present
studies suggest that cisplatin attenuates PPAR signal- RT-PCR. cDNA was synthesized in the first step, and
the selected sequence was amplified in the second. Theing by reducing its DNA binding activity without affect-
ing PPAR or RXR protein levels. In addition, we sequences of the sense and antisense primers used for
amplifications were: PPAR, 5-GGCTCGGAGGGCTexamined the effects of cisplatin on the expression of a
recently described tissue-specific coactivator of PPAR, CTGTCATC-3 and 5-ACATGCACTGGCAGCAGT
GGA-3; for PGC-1, 5-TCCTCTGACCCCAGACTPPAR-gamma-coactivator-1 (PGC-1). This nuclear pro-
tein has been shown to be a transcriptional coactivator CAC-3 and 5-TAGAGTCTTGGAGCTCCT-3; for
acyl-CoA, 5-ACTATATTTGGCCAATTTTGTG andof PPAR [10], PPAR(11), RXR [12], and other tran-
scription factors like nuclear respiratory factors (NRFs) 5-TGTGGCAGTGGTTTCCAAGCC-3; for l-carni-
tine palmitoyl transferase(l-CPT1), 5-CACGAAGAthat play critical roles in the regulation of oxidative me-
tabolism, cellular respiration, and adaptive thermogene- GCTAAACTTG-3 and 5-TATGAGAGGGTGCTG
CTT-3; and for glyceraldehydes-3-phosphate dehydro-sis [13, 14]. In situ hybridization studies demonstrate the
expression of PGC-1 in the mouse proximal tubule and genase (GAPDH), 5-CCCATCACCATCTTCCAGG
AGCG-3 and 5-GTCATGGATGACCTTGGCCAGthe thick ascending limb of Henle (TALH), two nephron
segments which also express high levels of PPAR and GG-3. GAPDH was used to normalize the results. After
performing the RT-PCR reactions, the products werefatty acid oxidation enzymes. Cisplatin inhibited the ex-
pression of PGC-1 on both nephron segments. Transient run on 6% poly-acrylamide gels. They were dried and
allowed to expose in Kodak radiography cassettes withtransfection studies confirmed the expression of PGC-1
in the nuclear compartment of LLCPK1 cells and its intensifying screens. The film was developed, and the
significant bands were analyzed and quantitated usingexpression increased PPAR activity in the proximal
tubule. Our studies suggest several mechanisms whereby Adobe Photoshop and the NIH imager program.
proximal tubule fatty acid oxidation is reduced in re-
Measurements of fatty acid oxidation enzymesponse to cisplatin, and further underscores the impor-
activities in LLCPK1 cellstance of having and intact PGC-1/PPAR function as a
homeostatic mechanism that modulate lipid oxidation Palmitoyl-CoA oxidase was measured in total cell ex-
tracts of LLCPK1 cells treated with and without cisplatinand energy balance during toxic injury to renal tubular
epithelial cells. using a similar fluorometric assay previously described
[8, 18]. Briefly, LLCPK1 cells grown to confluency in
10 cm Petri dishes were incubated in the absence and
METHODS
presence of cisplatin (0 to 100 mol/L) for various times.
In vivo model of cisplatin-induced acute renal failure To measure CPT I activity, mitochondrial fractions were
isolated as previously described [8]. After cisplatin incu-Male SV/129 mice approximately 5 to 6 weeks old,
weighing 25 to 30 grams, were assigned to treatment bation, cells were rinsed with phosphate-buffered saline
(PBS) followed by SET buffer [0.25 mol/L sucrose,groups (five animals per group) and received single intra-
peritoneal doses of vehicle (saline) or cisplatin (20 mg/kg 1 mmol/L ethylenediaminetetraacetic acid (EDTA), and
10 mmol/L Tris HCl pH 7.4]. Cells were then scraped intobody weight).
In our hands, the dose chosen was shown to produce 0.5 mL SET buffer, homogeneized, and mitochondrial
fractions were collected in the pellet after centrifugationnephrotoxicity without lethality after 3-day exposure to
cisplatin. Following treatment, the animals were sacri- at 10,000 g, followed by solubilization in 0.1 mL 0.2%
Triton X-100. CPT activity in mitochondrial fractionsficed and the kidneys were collected in 10% neutral buf-
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was assayed spectrophotometrically by the 5,5-dithio- mRNA on kidney sections from untreated and cisplatin
bis(2-nitrobenzoic acid (DTNB) method [19]. Incu- injected animals was performed as previously described
bations were carried out in a 0.6 mL mixture contain- [21].
ing 50 ug cell extract protein, 50 mmol/L Tris HCl pH
Transfection of PGC-1 increases PPAR8, 50 mmol/L sodium chloride, 5 mmol/L EDTA, 10%
transcriptional activityglycerol, 0.2% Triton X-100, 0.5 mmol/L DTNB, and
2.5 mmol/L l-carnitine. Plasmid and reporter constructs. pcDNA3.PGC-1 and
(PPRE)3TKLuc containing three copies of a known
Electrophoretic mobility shift assays PPARa response element derived from the peroxysomal
Nuclear extracts from LLCPK1 cells were prepared as acyl-CoA oxidase gene promoter (5-TTCCGAACGT
previously described [20] Double-stranded DNA oligo- GACCTTTGTCCTGGTCCCCTTTA-3) cloned into
nucleotide used for electrophoretic mobility shift assays the BamHI site of a construct containing the herpes
(EMSA) contained the PPRE consensus sequences and simplex virus thymidine kinase promoter linked to the
end-labeled using [-32P] ATP (Amersham Pharmacia luciferase gene (TKLuc) were generous gifts from Dr.
Biotech, Piscataway, NJ, USA) with T4 polynucleotide D.P. Kelly. LLCPK1 cells were maintained in Dulbecco’s
kinase and purified using Micro Bio-Spin 30 Chromatog- modified Eagle’s medium (DMEM) and fetal calf serum
raphy Columns (Bio-Rad Laboratory, Hercules, CA, (FCS) as described above. Near 75% confluency, the
USA). Binding reactions were assembled in a total vol- medium was changed to DMEM without FCS. Cells were
ume of 20 L and consisted of 6 g protein (nuclear transfected by the calcium phosphate coprecipitation
extract), 2 g poly (dI-dC) (Sigma, St. Louis, MO, USA), method. Briefly 4 g reporter construct and 500 ng of
and 4  104 cpm labeled probe, in a DNA protein bind- each expression construct or expression construct with-
ing buffer containing 20 mmol/L HEPES (pH 7.9), 4 out insert was used. The day after transfection, 50 m
mmol/L Tris (pH 7.9), 110 mmol/L potassium chloride, linoleic acid was added to the cells. The cells were har-
0.6 mmol/L EDTA, 0.6 mmol/L dithiothreitol (DTT), 5 vested 24 hours later in cell lysis buffer Promega and
mmol/L MgCl2, and 10% (vol/vol) glycerol. Some reac- luciferase activity was measured as previously described
tions also contained unlabeled “competitor” double- [10]. All transfection data are presented as means 
stranded DNA oligonucleotides at 50-fold molar excess standard errors of at least three separate transfection
over the probe. Supershift was performed by addition experiments done in triplicate.
of 2 g of specific PPAR antisera into binding reaction
and overnight incubation at 4	C prior to adding the probe. Transient transfection of GFP-PGC-1 in LLCPK1 cells
Protein DNA complexes were allowed to form for 20
LLCPK1 cells were cultured on glass coverslips inminutes at room temperature, resolved on a 4% nonde-
DMEM media supplemented with 15 mmol/L N-2-hy-naturing polyacrylamide gel, and visualized by autoradi-
droxyethylpiperazine-N-2-ethanesulfonic acid (HEPES),ography. At least four preparations of nuclear extracts
2.5 mmol/L l-glutamine, 5% calf serum, and 100 units/mLwere made and tested in the EMSA experiments [20].
penicillin, 100 g/mL streptomycin, and 0.25 g/mL am-
photericin B in a 5% carbon dioxide incubator at 37	C.Western blot analysis
Cells were transfected with a total of 15 ng GFP-PGC-1Nuclear extracts from LLCPK1 cells treated with and
plasmid DNA (a gift from Dr. B.M. Spiegelman) in 6without cisplatin (50 mol/L) for various times were ob-
cm diameter dishes using the calcium phosphate methodtained as described above for the EMSA experiments.
[10]. Twenty-four hours following transfection, livingProteins were separated by sodium dodecyl sulfate-poly-
cells were examined by phase contrast and epifluores-acrylamide gel electrophoresis (SDS-PAGE), transferred
cence microscopy using10 0.30 na Plan-Neofluar objec-to nitrocellulose membranes (Schleicher & Schuell, Keene,
tive (Carl Zeiss, Inc., Thornwood, NY, USA), a filterNH, USA), and probed with affinity-purified antibodies
set specific for GFP (#31001 Chroma Technology Corp.,directed against PPAR and RXR.
Brattleboro, VT, USA) and a 100 W mercury arc illumi-
In situ hybridization for PGC-1 mRNA nator (Atto Instruments, Inc., Rockville, MD, USA).
Digital images were collected from the SCSI port of anEffects of cisplatin. Mouse PGC-1 nucleotides 99-2485
8-bit CCD camera (C5985; Hamamatsu Photonic Sys-(GenBank #AF 049330) were introduced into pBlue-
tems, Bridgewater, NJ, USA).script SK- at the NotI site. The plasmid was linearized
with EcoRI and the PGC-1 antisense RNA probe (ap-
Statistical analysesproximately 200 bases) was labeled with digoxigenin
Results are mean  SE. Comparison between valuesUTP using T3 RNA polymerase according to the manu-
was determined by the Student t test. A P value less thanfacturer’s recommendation (Roche Diagnostics, India-
napolis, IN, USA). In situ hybridization of PGC-1 0.05 was considered significant.
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studies have demonstrated that I/R-induced ARF was
accompanied by a reduction in the expression and en-
zyme activity of fatty acid oxidation enzymes, we exam-
ined the potential effects of cisplatin-induced ARF on
the mRNA expression of peroxisomal fatty acid oxida-
tion enzyme acyl-CoA oxidase. Quantitative RT-PCR
analysis of mRNA levels of acyl-CoA demonstrated that
this mRNA as well as mRNA levels for mitochondrial
fatty acid oxidation enzymes medium chain acyl-CoA
dehydrogenase (MCAD) and CPT-1 were also signifi-
cantly reduced as early as 24 hours of cisplatin treatment.
Figure 1A shows the effects of cisplatin on mRNA levels
of acyl-CoA at day 3. To exclude the possibility that
the down-regulated expression of acyl-CoA in cisplatin-
treated mice was not due to a general reduction in kidney
gene transcription, a control mRNA was also analyzed.
Levels of mRNA encoding GAPDH housekeeping gene
were not different in the cisplatin group compared with
controls (see Figures 1 A and B).
To further examine the mechanisms of inhibition of
fatty acid oxidation by cisplatin at the cellular level, we
next performed experiments in a proximal tubule cell
line LLCPK1. Previous studies in this cell line have dem-
onstrated that this represents a useful model to study
the cellular mechanisms of proximal tubule cell death.
Those studies recently published by Kaushal et al dem-
onstrated that at a dose of 50 mol/L cisplatin stimulates
caspase 3 activity after 9 hours of incubation, and mem-
brane damage was not detected until after 12 hours of
incubation [22]. Therefore, most of the studies presented
in this article in LLCPK1 cells exposed to cisplatin were
performed using a dose of 50mol/L cisplatin for variousFig. 1. Blot analysis of acyl coenzyme A (acyl-CoA) mRNA levels in
times. We first quantitated mRNAs of acyl-CoA andmouse kidney. Total cellular RNA from mice kidneys of each experi-
mental condition described above was used to quantitate acyl-CoA CPT-1 using RT-PCR. As shown in Figures 2 A and B,
mRNA as described in the Methods section. After intraperitoneal (IP) CPT-1 mRNA levels initially increased significantlyinjection of cisplatin, creatinine levels rose. (A) The amount of cisplatin
within the first 3 hours of incubation with 50 mol/Lafter 3 days and its effect on acyl-CoA oxidase (ACoA) and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). (B) The laser densitome- cisplatin, but then the levels were reduced significantly
try scanning of RNA blots for ACoA from four separate experiments. at the end of 12 hours of incubation. Acyl-CoA mRNAAn arbitrary number of 1 was assigned to the density measured in the
levels were also significantly reduced at the end of 12band corresponding to control animals that did not receive cisplatin.
Data are means  SE from four separate experiments. *P 
 0.002 hours of incubation with 50 mol/L cisplatin. We also
compared with vehicle-treated mice. examined the effects of cisplatin on enzyme activities of
acyl-CoA oxidase, and mitochondrial CPT. As shown in
Figure 2C, cisplatin incubation led to a time-dependent
reduction in enzyme activity of acyl-CoA by 40%. butRESULTS
a major reduction (70%) also was seen on CPT-1 activity
Studies in mouse kidney at the end of 12 hours of incubation with 50 mol/L
Renal function was evaluated in mice subjected to cisplatin.
intraperitoneal injection of either saline (control) or cis-
Studies in LLCPK1 cellsplatin (20 mg/kg body weight) by determining blood urea
nitrogen and serum creatinine levels. Compared to mice Cisplatin decreases PPAR/RXRDNA binding activ-
administered vehicle, mice administered a single dose of ity. To determine whether cisplatin influences the inter-
cisplatin developed ARF with significantly higher creati- action of PPAR with cognate DNA binding sites, the
nine levels appreciable after 3 days of the administration acyl-CoA PPRE element was used in EMSA to assess
of cisplatin [control animals 0.2  0.06 versus cisplatin- PPAR DNA binding activity. The PPRE oligonucleo-
tide probe formed one major DNA protein complextreated mice 1.1 0.2 mg/dL (N 5)]. Since our previous
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Fig. 2. Effects of cisplatin on mRNA levels and fatty acid oxidation
enzyme activities in LLCPK1 cells. (A) Blot analysis of LLCPK1 cells
treated with 50 mol/L cisplatin for various times Total RNA was
isolated and reverse transcription-polymerase chain reaction (RT-PCR)
reactions were carried out using specific primers for l-carnitine palmi-
toyl transferase (l-CPT-I), acyl coenzyme A (acyl-CoA) and glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH) as described in the Meth-
ods section. (B and C ) Laser densitometry scanning of RNA blots for
CPT and acyl-CoA oxidase (ACoA) from four separate experiments.
An arbitrary number of 1 was assigned to the density measured in the
band corresponding to control animals that did not receive cisplatin. .
Data are means  SE from four separate experiments. *P 
 0.002
compared with vehicle-treated LLCPK1 cells. (D and E ) The changes
in enzyme activities of LLCPK1 cells treated with 50 mol/L cisplatin
for various times. CPT and ACoA activities were measured as described
in the Methods section. Data are means  SE from four separate
experiments. *P 
 0.004 compared with vehicle treated LLCPK1 cells.
(Fig. 3A) This complex represents specific acyl-CoA hours of cisplatin-treated cells (lanes 1 through 24). The
gel shift results shown in Figure 3A reveal that the forma-PPRE protein interaction based on competition studies
with a molar excess of unlabeled PPRE or mutated tion of the PPAR/RXR complex is gradually reduced
after 6 hours and completely disappeared after 12 hoursPPRE (not shown). Figure 3A shows the comparison
of PPRE binding activity between probe alone without of treatment with 50 mol/L cisplatin. Figure 3B depicts
the results of supershift analysis using PPAR antibody.nuclear extract (lane P), and the presence of nuclear
extracts of control untreated cells (lane 0) and up to 24 Lane 1 shows nuclear extracts in the presence of the
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Fig. 3. Effect of cisplatin on binding of PPAR
to the acyl coenzyme A (acyl-CoA)-PPRE
in nuclear extracts from LLCPK1 cells. (A)
Electrophoretic mobility shift assay (EMSA)
was performed using 32P-labeled acyl CoA oxi-
dase (AcoA) PPRE binding element and nu-
clear extracts prepared from LLCPK1 cells
treated with cisplatin. Lane P shows the DNA
protein reaction in the absence of nuclear ex-
tracts, and lanes 0 to 24 hours show the
changes in the amount of DNA protein com-
plex from cells treated with cisplatin from 0
to 24 hours. (B) Lane 1 represents control
nuclear extracts in the absence of cisplatin and
lane 2 represents nuclear extracts of control
cells but in the presence of PPAR antibody.
PPRE-labeled probe without the antibody and lane 2
shows nuclear extracts incubated with PPAR antibody.
These results indicate that cisplatin decreases DNA
binding activity to the PPAR/RXR heterodimer.
Cisplatin effects on nuclear levels of PPAR and RXR
The results shown above indicate that cisplatin attenu-
ates PPAR signaling by reducing its DNA binding ac-
Fig. 3. (Continued) (C ) Effect of cisplatin on protein levels of PPARtivity. Therefore, nuclear levels of PPAR protein were
and RXR. LLCPK1 cells were treated for various times in the absence
measured to determine whether the altered binding ac- and presence of 50 mol/L cisplatin, nuclear extracts were prepared and
Western blot analysis was done using antibodies recognizing PPAR ortivity of PPAR/RXR was due to diminished availabil-
RXR as described in the Methods section.ity of PPAR. As expected, the majority of PPAR pro-
tein (a molecular weight of about 50 kD) was detected
in the nucleus. Surprisingly, cisplatin conditions did not
alter the nuclear levels of PPAR. Additional immu- sion of PGC-1 on both the proximal tubule as well as
noblot studies using a RXR antibody failed to detect the TALH. This effect was apparent after the first 24
cisplatin-induced changes in the nuclear protein levels hours of treatment, even in the absence of significant
of RXR (see Fig. 3C). necrosis of the proximal tubule, which was not visually
apparent until 3 to 4 days of cisplatin treatment (see
Cisplatin decreases PGC-1 expression in the Figure 4).
mouse kidney
Cisplatin decreases PGC-1 mRNA levels inIn situ hybridization for PGC-1 mRNA identified the
mouse kidneycells of the proximal tubule and thick ascending limb
of Henle (TALH) as the principal sites of PGC-1 expres- Mouse kidney total RNA was prepared from mice
sion in 6-week-old mice. Cisplatin (20 mg/kg body weight) that have received either intraperitoneal saline (vehicle)
or cisplatin. PGC-1 mRNA was quantitated by RT-PCRgiven intraperitoneally caused a reduction in the expres-
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Fig. 4. In situ hybridization for localization
of peroxisome proliferator activated receptor
gamma coactivator-1 (PGC-1) mRNA in nor-
mal and cisplatin-treated mice. The hybridiza-
tion of a PGC-1 RNA antisense probe can be
seen in cells of proximal tubules (PT) and
thick ascending limbs of Henle (TALH), pri-
marily in the inner cortex in normal mouse
kidneys (A and C) noted by a dark brown stain-
ing. The staining was considerably less in the
cisplatin-treated kidneys (B and D). Original
magnification for (A and B) 240; (C and D)
480.
Fig. 8. Peroxisome proliferator activated receptor gamma coactivator-1 (PGC-1) localizes to nuclei in LLCPK1 cells. Living LLCPK1 cell transfected
with GFP-PGC-1 were examined 24 hours post-transfection by epifluorescence (A) and phase contrast (B) microscopy. The epifluorescence image
contains nuclei expressing low and high level of GFP-PGC. At higher levels of expression, PGC-1 localized to nuclear speckles.
as described in the Methods section. As shown in Fig- Cisplatin decreases PGC-1 mRNA levels in
LLCPK1 cellsure 5, PGC-1 mRNA in mouse kidney tissue was signifi-
cantly reduced after the first 2 days of cisplatin injection, LLCPK1 cells were grown to confluency for 48 hours
similar to what we have observed in our in situ hybridiza- and subjected to cisplatin (50 mol/L) for 3, 6, and 12
hours. PGC-1 mRNA levels were quantified by RT com-tion studies.
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Fig. 6. Effect of cisplatin on peroxisome proliferator activated receptor
gamma coactivator-1 (PGC-1) mRNA levels in LLCPK1 cells. (A) RNA
blots from LLCPK1 cells treated with 50 mol/L cisplatin for various
times Total RNA was isolated and reverse transcription-polymerase
chain reaction (RT-PCR) reactions were carried out using specific
primers for PGC-1 and glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) as described in the Methods section. (B) Laser densitometry
scanning of RNA blots from four separate experiments. An arbitrary
number of 1 was assigned to the density measured in the band corre-Fig. 5. Effect of cisplatin on peroxisome proliferator activated receptor
sponding to control animals that did not receive cisplatin. Data aregamma coactivator-1 (PGC-1) mRNA levels in mouse kidney. (A) RNA
means  SE from four separate experiments. *P 
 0.002 comparedblots from mice treated with vehicle (control) or cisplatin for 2 days.
with vehicle-treated LLCPK1 cells.Total cellular RNA from mice kidneys was extracted and used to per-
form PGC-1 RNA quantification by reverse transcription-polymerase
chain reaction (RT-PCR) analysis as described in the Methods section.
(B) Laser densitometry scanning of RNA blots from four separate ex-
periments. An arbitrary number of 1 was assigned to the density mea-
bules was significantly reduced between 6 to 12 hours ofsured in the band corresponding to control animals that did not receive
cisplatin. Data are means  SE from four separate experiments. *P 
 incubation with cisplatin.
0.004 compared with vehicle-treated mice.
Transfection of PGC-1 in LLCPK1 cells: Effects on
PPAR transcriptional activity
To examine the effect of PGC-1 on PPAR activitypetitive PCR using a sense primer 5-TCCTCTGACCC
cotransfection studies were performed in LLCPK1 cells.CAGAGTCAC-3 nt 777-796 and an anti-sense primer
A target promoter plasmid containing a PPAR response5-TAGAGTCTTGGAGCTCCTG-3 nt 1202-1220 de-
element (PPRE) derived from the peroxisomal acyl-CoArived from the expressed sequence tags (EST) sequences.
oxidase gene promoter multimerized upstream of theThe expected 443 base pair fragment was cloned and
thymidine kinase minimal promoter (PPRE3TKLuc) wassequenced for verification. Figure 6 shows that the
amount of PGC-1 mRNA levels in mouse proximal tu- employed in these studies. As shown in Figure 7, cotrans-
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fection of TKLuc 3xPPRE in the presence of linoleate
had a small but significant effect on PPAR activity.
Cotransfection of PGC-1 increased the level of PPAR-
mediated activation by at least 3-fold and cotransfection
of PGC-1 in the presence of linoleate resulted in a sig-
nificant increased in PPAR activity by at least 6-fold.
Transfection of GFP-PGC1 in LLCPK1 cells
Living LLCPK1 cells were transfected with GFP-
PGC1 and then examined 24 hours post-transfection by
epifluorescence microscopy (Figure 8). PGC-1 was local-
ized to the nuclei. At low levels of expression, nuclear
staining was diffuse. At higher levels of expression, GFP-
PGC-1 localized to nuclear speckles.
DISCUSSION
In this article we have extended our observations of
I/R-induced inhibition of fatty acid oxication to the toxic
model of cisplatin-induced ARF and renal tubular epi-
thelial cell injury. Cisplatin significantly decreased both
mRNA levels and enzyme activities of peroxisomal acyl-
CoA in mouse kidney and in LLCPK1 cells in culture. In
Fig. 7. Peroxisome proliferator activated receptor gamma coactivator-1
addition in the present studies, we observed that cisplatin (PGC-1) enhances PPAR-mediated transactivation. The heterologous
promoter reporter construct PPRE3 TKLuc was transiently transfectedalso inhibited mRNA levels and enzyme activities of mito-
into LLCPK1 cells. Expression construct encoding PGC-1 was cotrans-chondrial CPT, the rate-limiting enzyme for mitochon-
fected in the absence and presence of 75 mol/L linoleoic acid as
drial fatty acid oxication and energy production [23]. indicated. Bars represent (mean  standard error) relative luciferase
units normalized to the activity of PPRE3 TKLuc. All transfection dataTherefore, inhibition of fatty acid oxidation in the proxi-
represent the means of at least three independent experiments.mal tubule following exposure to cisplatin likely consti-
tutes an adaptive metabolic response to renal epithelial
cell injury, which should result in decreased energy pro-
duction. However, it is also possible that reduced expres- that the recruitment of transcriptional coactivators to the
sion of peroxisomal acyl-CoA, mitochondrial CPT, and ligand-binding domain of PPARs can lead to interaction
other PPAR target genes may diminish fatty acid per- with the basal transcription machinery and ultimately
oxisomal and mitochondrial flux and therefore reduce with RNA polymerase II, which will result in enhance-
the accumulation of toxic long chain fatty acid intermedi- ment of the transcriptional activity of PPARs. Our study
ates such as long chain acylcarnitines and long chain is the first one to examine the nephronal compartmenta-
acyl-CoA. This is particularly relevant to toxic renal epi- tion of coactivator PGC-1 in the kidney, as well as the
thelial cell injury since in previous studies we demon- first one to show in vivo regulation of PGC-1 mRNA
strated that long chain acylcarnitines impaired proximal levels by cisplatin. In situ hybridization studies demon-
tubule cell function via its effects on sodium/potassium strated that the proximal tubule and the TALH, the two
ATPase activity and membrane integrity [6, 7]. nephron segments that express high mRNA and protein
The results of our EMSA experiments suggest that levels of PPAR, and fatty acid oxidation enzymes acyl-
cisplatin alters PPAR/RXR DNA binding activity. CoA, CPT, and MCAD [26, 27] did also express high
Immunoblotting studies demonstrated that cisplatin has mRNA levels of PGC-1. Cisplatin inhibited the expres-
no effect on the nuclear levels of PPAR or RXR. The sion of PGC-1 in both nephron segments in mouse kid-
mechanism for this inhibition is unclear at this time. ney and also in LLCPK1 cells. Inhibition of PGC-1 and
However, the inhibition of PPARDNA binding activity fatty acid oxidation preceded the development of acute
by cisplatin would certainly explain our observed cis- tubular necrosis, an observation that suggests that this
platin-induced inhibition of the expression of PPAR physiologic response is not a consequence of proximal
target genes acyl-CoA and CPT. tubule cell death.
Recent studies suggest that the regulation of fatty acid Therefore, in addition to cisplatin-induced inhibition
oxidation by PPAR in kidney tissue may require the of PPAR DNA binding activity, reduced expression of
presence of tissue specific coactivator(s) in addition to PGC-1 represents another mechanism by which cisplatin
decreases the expression and enzyme activity of fatty acidendogenous ligands [24, 25]. Those studies have shown
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